Literature DB >> 11214878

Labelling of Re-ABP with 188Re for bone pain palliation.

C Arteaga de Murphy1, G Ferro-Flores, M Pedraza-López, L Meléndez-Alafort, B Y Croft, F M Ramírez, J Padilla.   

Abstract

Etidronate and medronate have been labelled with technetium-99m (99mTc-HEDP, 99mTc-MDP) for bone scanning and, with rhenium-188 (188Re-HEDP) to palliate the pain resulting from bone metastases. The objective of this study was to label alendronate, ABP, a new bisphosphonate, with SnF2-reduced-188Re. The reagents for the 5 mg ABP kit were SnF2, KReO4 and gentisic acid at acid pH. The chemical, spectroscopic and microscopic characteristics, quality control, rat bone uptake of [188Re]Re-ABP and similarities with 99mTc-ABP are presented. We conclude that this is a promising new radiopharmaceutical for bone metastases pain palliation.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11214878     DOI： 10.1016/s0969-8043(00)00296-7

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN： 0969-8043            Impact factor:   1.513


  2 in total

1.  188Re-labelled gemcitabine/bisphosphonate (Gem/BP): a multi-functional, bone-specific agent as a potential treatment for bone metastases.

Authors:  Amal A El-Mabhouh; John R Mercer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-02-12       Impact factor: 9.236

2.  Preparation, Characterization, and Preliminary Imaging Study of [188Re]Re-Ibandronate as a Novel Theranostic Radiopharmaceutical for Bone Metastasis.

Authors:  Tingting Xu; Yingwei Wang; Zan Chen; Hanxiang Liu; Songsong Yang; Guangfu Liu; Yan Zhao; Wenhui Fu; Lin Liu; Ke Xiang; Dengsai Peng; Yue Chen
Journal:  Contrast Media Mol Imaging       Date:  2022-02-25       Impact factor: 3.161
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.